5results about How to "Induce immune response" patented technology

The invention relates to synthetic HIV envelope proteins, vectors and associated compositions, as well as methods for inducing protective immunity against human immunodeficiency virus (HIV) infection. Viral expression vectors encoding synthetic HIV envelope proteins can be used in vaccines to enhance protective immunity against HIV.

The present invention discloses a bacterial flagellin lacking a hypervariable region structural domain and a preparation method and application thereof. The bacterial flagellin lacking a hypervariable region structural domain is a FliC H7 The amino acid at position 178 to position 497 of the hypervariable region is missing. The present invention constructs a truncated recombinant Escherichia coli flagellin FliC by deleting the middle hypervariable region of flagellin NC In vitro Caco‑2 cell model detection revealed that FliC NC With FliC H7 Similar and good TLR5 receptor activity can activate TLR5 signaling pathway; in vivo, FliC NC Recombinant flagellin can also induce high levels of IgG antibodies against the model antigen FaeG in vivo and inflammatory genes related to humoral and cellular immunity in spleen cells.

This invention provides the application of VdPL9-3 protein in improving plant resistance and / or inducing plant immune responses. The amino acid sequence of VdPL9-3 protein is shown in SEQ ID NO.1. It is a highly efficient plant immune activating protein that can effectively improve plant resistance and enhance the host's ability to defend against pathogens.

The application discloses a specific T cell epitope peptide screened by a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicine, and its technical points are: the application provides a plurality of CD4+ T and CD8+ T cell epitope polypeptides of the novel coronavirus, and the genes, recombinant proteins or complexes containing the epitope polypeptides, sensitized antigen presenting cells and specific immune effector cells for the epitope polypeptides are used in the development of a novel coronavirus vaccine and the treatment of diseases.The polypeptide provided by the application is screened from the peripheral blood sample of a recovered person who breaks through infection of Omicron BA.5 after inactivated vaccine booster vaccination, and can safely and effectively induce CD4+ T and CD8+ T cell immune responses to the novel coronavirus protein, and has important guiding significance for the development of a novel coronavirus vaccine.

Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.